

535,609
Rec'd PCT/PTO 19 MAY 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/045634 A1

(51) International Patent Classification⁷: **A61K 38/00**

Philip, J. [GB/US]; Arriva Pharmaceuticals Inc., 2020 Challenger Drive, Alameda, CA 94501 (US).

(21) International Application Number:
PCT/GB2003/005049

(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date:
20 November 2003 (20.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/427,702 20 November 2002 (20.11.2002) US

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): ARRIVA-PROMETIC INC. [CA/CA]; 6100 Royalmount Avenue, Montreal, Quebec, H4P 2R2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BATHURST, Ian, C. [US/US]; Arriva Pharmaceuticals Inc., 2020 Challenger Drive, Alameda, CA 94501 (US). PEMBERTON, Phillip, A. [NZ/US]; Arriva Pharmaceuticals Inc., 2020 Challenger Drive, Alameda, CA 94501 (US). SUNDIN, David, J. [US/US]; Arriva Pharmaceuticals Inc., 2020 Challenger Drive, Alameda, CA 94501 (US). MAYHEW, James, W. [US/US]; Dow Pharmaceutical Science, 1330A Redwood Way, Petaluma, CA 94954-1169 (US). ANGEL, Arturo, J. [US/US]; Dow Pharmaceutical Sciences, 1330A Redwood Way, Petaluma, CA 94954-1169 (US). BARR,

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS

(57) Abstract: Compositions containing a protease inhibitor and methods of use and production are described. The compositions contain an effective amount of a protease inhibitor in a carrier or diluent and are used for the treatment of inflammatory or hyperproliferic mucocutaneous disorders. The carrier or diluent is preferably a gelling agent, and the composition is a topical gel formulation containing alpha 1-antitrypsin in an aqueous liquid or viscous gel formulation.

WO 2004/045634 A1

34. Use according to claim 11, wherein the inhibitor is α 1-antitrypsin and the disorder is ichthyosis.

~~5 35. Use according to claim 11, wherein the inhibitor is α 1-antitrypsin and the disorder is psoriasis.~~

36. Use according to claim 11, wherein the inhibitor is α 1-antitrypsin and the disorder is atopic dermatitis.

10

Amended sheet